Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CTSV | O60911 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9400712 | 0.91 | KCNH2 (0.63) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL9400646 | 0.88 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL6765948 | 0.87 | HTR6 (0.59) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL8589137 | 0.85 | HTR6 (0.61) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL8542497 | 0.83 | MAPT (0.53) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL17505193 | 0.81 | PARP1 (0.52) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL27658173 | 0.81 | MEN1 (0.50) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL3571118 | 0.79 | ALDH1A1 (0.51) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL17505206 | 0.79 | CTSV (0.52) | MAPTMEN1KMT2AALDH1A1POLB | |
| SCHEMBL17505160 | 0.79 | PARP1 (0.52) | MAPTMEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018073828-A1 | DNA PRIMASE AND GYRASE INHIBITORS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2018-04-26 | — | — | WO | disclosed |
| US-9359285-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-09 | — | — | US | disclosed |
| US-8865918-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
| US-8519158-B2 | Androgen receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-11-01 | — | — | US | disclosed |
| WO-2005090282-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-29 | — | — | WO | disclosed |
| US-5328922-A | Anxiolytic and antidepressant activity | BEECHAM GROUP P.L.C. (GB) | 1994-07-12 | — | — | US | disclosed |
| WO-1993018026-A1 | INDOLE UREAS AS 5-HT1C RECEPTOR ANTOGONISTS | BEECHAM GROUP PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
| EP-0550507-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | Beecham Group p.l.c. (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992005170-A1 | INDOLE UREAS AS 5 HT RECEPTOR ANTAGONIST | BEECHAM GROUP PLC (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099720-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | MAPT 4233/4885MEN1 2404/4885KMT2A 2825/4885 |
| US-20140005186-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | AR, SHBG, NR5A1 | MAPT 4233/4885MEN1 2404/4885KMT2A 2825/4885 |
| US-20070254875-A1 | Androgen Receptor Modulator Compounds and Methods | AR, SHBG, NR5A1 | MAPT 4233/4885MEN1 2404/4885KMT2A 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.